Search This Blog

Wednesday, July 22, 2026

Arrowhead's plozasiran meets endpoints in Phase 3 in severe hypertriglyceridemia, Ionis drops

 

Arrowhead's plozasiran meets all primary, secondary endpoints in positive Phase 3 SHASTA-3 and SHASTA-4 trials in severe hypertriglyceridemia

  • Arrowhead plans to submit a U.S. sNDA for plozasiran in severe hypertriglyceridemia by year-end.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)